Anterra Capital
VC Fund
Amsterdam, The Netherlands
Anterra Capital is an independent growth capital fund. They invest in fast growing companies that are working to make the global food supply chain safer, more efficient and more sustainable. Their focus is on supporting the growth of companies who are commercializing novel technologies and services. They invest across the food supply chain fromnovel agro inputs and precision farming through to smarter logistics and consumer safety. They do not invest in other funds, land, operating assets, or other capital intensive businesses.They are a lead investor taking significant minority equity positions and performing an active role on the boards of the companies they support. At the time they invest, their companies typically already generate revenue and have great growth prospects. They target investments of EUR 1M to EUR 15M per company and often support their portfolio companies in raising additional capital from professional investors including from their own financial partners. Importantly, they are long-term investors. They focus on working closely with management teams to build lasting value.
- Total investments:
- 57
- Last investment:
- Lead investor:
- 39%
- Fund size:
- $260M
- Last fund:
Last updated:
For AI agents: llms.txt
Industries Anterra Capital invests in
Stages Anterra Capital invests in
Countries Anterra Capital invests in
Round sizes
Contacts
| Name | Phone | Socials | |
|---|---|---|---|
Round size
- Seed
- $3M–$10M
- Series A
- $3.3M–$26M
- Series B
- $8.3M–$46M
Investment Focus
Industry
- Biotechnology 11 (19%)
- AgTech 5 (9%)
- Agriculture 5 (9%)
- Software 4 (7%)
- Food and Beverage 4 (7%)
Stage
- Series B 14 (25%)
- Series A 11 (19%)
- Seed 5 (9%)
- Series C 4 (7%)
- Funding Round 4 (7%)
Country
- United States 17 (30%)
- United Kingdom 4 (7%)
- France 2 (4%)
- India 1 (2%)
- Germany 1 (2%)
Team
| Name | Title | Investments | Links | |
|---|---|---|---|---|
Adam Anders
Managing Partner
|
Managing Partner | Total investments: 2 | Find email | |
Brett Chevalier
Venture Partner
|
Venture Partner | Total investments: 0 | Find email | |
Brett Wong
Principal
|
Principal | Total investments: 0 | Find email | |
Maarten Goossens
Principal
|
Principal | Total investments: 0 | Find email | |
Philip Austin
Founding Partner
|
Founding Partner | Total investments: 6 | Find email | |
| See all 8 team members → | ||||
Investments
| Company | Description | Round | Links |
|---|---|---|---|
Anchr
|
Anchr develops an AI platform for automating knowledge work and workflow execution. The software connects to business data sources, ingests documents, and structures information for retrieval via chat interfaces and APIs. Core capabilities include document parsing, semantic search, agent-style task orchestration, and integrations with third‑partytools. Typical use cases include research synthesis, content drafting, customer support assistance, and internal reporting. The offering targets teams seeking to unify unstructured content and trigger actions from natural‑language prompts while retaining control over data and access. | $5.8M / Pre-Seed / Mar 10, 2026 | |
Berkeley Yeast
|
Berkeley Yeast engineers yeast strains to help brewers create beers that are delicious and sustainable. The company was founded by Berkeley PhDs in 2017. Its headquarters is based in Oakland, California. They consume around the world, from regional specialties to staples used by billions of people daily. This includes beer and wine, but also bread,cheese, vinegar, soy sauce, fish sauce, kombucha, miso, chocolate, and others. The list is long and reveals a broad and exciting horizon. | Series A / Dec 23, 2025 | |
Animol Discovery
|
Animol is building its own pipeline of break-through proprietary veterinary small molecules led by a team of animal health industry experts with vast experience in bringing drugs to market. With our unique and powerful technology platform we deliver innovative medicines that are specifically designed for the needs of veterinary patients. | $12M / Series C / Oct 17, 2025 | |
AgrigateOne
|
AgrigateOne is an online platform that enables openness between growers and buyers and gets data about agriculture and marine logistics. | $7.2M / Seed / Aug 08, 2025 | |
BiomEdit
|
BiomEdit is an innovation company that discovers, designs, and develops novel probiotics, microbiome derived bioactives, and engineered microbial medicines to address unmet needs in animal health. Our ambition is to create solutions to some of the most important problems in animal agriculture and food security by leveraging the potential of themicrobiome. BiomEdit’s technology is based on a unique platform that utilizes high-throughput sequencing and data analytics to rapidly discover and screen novel probiotic species and bioactive molecules. These can then be engineered to confer thermostability, enhanced production of beneficial metabolites, or expression of immune modulating proteins. These probiotics and microbially-derived compounds represent the next generation of products designed to promote animal health without the use of antibiotics. | $18.4M / Series B / Jul 15, 2025 | |
Dalma
|
Dalma offers transparent, subscription-based health insurance that covers pets, reimbursing costs related to illnesses, injuries, and preventive care. | $21.8M / Series B / Mar 17, 2025 | |
|
Dalma
|
Dalma offers transparent, subscription-based health insurance that covers pets, reimbursing costs related to illnesses, injuries, and preventive care. | $13M / Series B / Dec 20, 2024 | |
|
Animol Discovery
|
Animol is building its own pipeline of break-through proprietary veterinary small molecules led by a team of animal health industry experts with vast experience in bringing drugs to market. With our unique and powerful technology platform we deliver innovative medicines that are specifically designed for the needs of veterinary patients. | $9.5M / Series C / Nov 15, 2024 | |
|
Edge Animal Health
|
Animal Health | $11M / Series B / Jun 17, 2024 | |
Bonito Biosciences
|
Bonito Biosciences is a biotechnology research firm specializing in tissue-selective drug delivery for oligonucleotides and macromolecules. | $9M / Seed / May 31, 2024 | |
| See all 57 investments → | |||
Co-Investors
Finistere Ventures
9 deals together
Novalis LifeSciences
6 deals together
Eight Roads Ventures
5 deals together
Cavallo Ventures
4 deals together
Endeavor8
4 deals together
Northpond Ventures
4 deals together
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar industry
Similar stage
Featured in Investor Lists
Recommended lists
FAQ
What does Anterra Capital invest in?
Anterra Capital invests primarily in Biotechnology, AgTech and Agriculture startups, most often at Series B and Series A stage. Most of the 57 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.
What is Anterra Capital's check size?
Anterra Capital typically joins rounds of $3M–$10M at Seed, $3.3M–$26M at Series A and $8.3M–$46M at Series B. These ranges are 10th–90th percentile round sizes calculated from confirmed public funding rounds, so they are a realistic guide to the rounds Anterra Capital participates in.
How do I contact Anterra Capital?
Public channels for Anterra Capital include LinkedIn, X (Twitter) and the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.
Who are the partners at Anterra Capital?
The team at Anterra Capital includes Adam Anders (Managing Partner), Brett Chevalier (Venture Partner) and Brett Wong (Principal), among 8 team members tracked by Shizune. The Team section lists each member with their title, investment count and links.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
